Neurocognition, Insight and Medication Nonadherence in Schizophrenia: A Structural Equation Modeling Approach

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Boyer, Laurent ^a   Cermolacce, Michel ^b   Dassa, Daniel ^c   Fernandez, Jessica ^a   Boucekine, Mohamed ^a   Richieri, Raphaelle ^a,b   Vaillant, Florence ^b   Dumas, Remy ^a,b   Auquier, Pascal ^a   Lancon, Christophe ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c La Conception University Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; COGNITION; CROSS-SECTIONAL STUDY; DSM-IV; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION ADHERENCE RATING SCALE; MEMORY; NEGATIVE SYNDROME; NEUROCOGNITION; PATIENT COMPLIANCE; POSITIVE SYNDROME; PROSPECTIVE STUDY; RATING SCALE; SCALE TO ASSESS UNAWARENESS OF MENTAL DISORDER; SCHIZOPHRENIA; STRUCTURAL EQUATION MODELING;

ADULT; ATTENTION; AWARENESS; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MEMORY; MIDDLE AGED; MODELS, PSYCHOLOGICAL; OUTPATIENTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84868118727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047655     Document Type: Article

References (50)

1. Davis JM, Chen N, (2003) Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64 Suppl 16: 24-33.
2. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, et al. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247.
3. Leucht S, Heres S, (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 Suppl 5: 3-8.
4. Masand PS, Roca M, Turner MS, Kane JM, (2009) Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 11: 147-154.
5. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, et al. (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70 Suppl 4: 1-46; quiz 47-48.
6. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, et al. (2003) Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 63: 49-58.
7. Green MF, Kern RS, Braff DL, Mintz J, (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26: 119-136.
8. Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, et al. (2010) Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry 44: 921-928.
9. Fenton WS, Blyler CR, Heinssen RK, (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23: 637-651.
10. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, et al. (2008) Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry 49: 170-176.
11. Osatuke K, Ciesla J, Kasckow JW, Zisook S, Mohamed S, (2008) Insight in schizophrenia: a review of etiological models and supporting research. Compr Psychiatry 49: 70-77.
12. Lysaker PH, Carcione A, Dimaggio G, Johannesen JK, Nicolo G, et al. (2005) Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life. Acta Psychiatr Scand 112: 64-71.
13. Buchanan A, (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787-797.
14. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, et al. (1999) The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 187: 102-108.
15. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, et al. (2006) Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 83: 53-63.
16. Lincoln TM, Lullmann E, Rief W, (2007) Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull 33: 1324-1342.
17. Yen CF, Chen CS, Ko CH, Yeh ML, Yang SJ, et al. (2005) Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci 59: 403-409.
18. Tait L, Birchwood M, Trower P, (2003) Predicting engagement with services for psychosis: insight, symptoms and recovery style. Br J Psychiatry 182: 123-128.
19. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R, (2011) Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res 132: 42-49.
20. Staring AB, van der Gaag M, Duivenvoorden HJ, Weiden PJ, Mulder CL, (2011) Why do patients with schizophrenia who have poor insight still take antipsychotics? Memory deficits as moderators between adherence belief and behavior. J Psychiatr Pract 17: 320-329.
21. Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, et al. (2002) Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 53: 1319-1321.
22. Smith CM, Barzman D, Pristach CA, (1997) Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 37: 147-154.
23. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, et al. (2005) Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 62: 717-724.
24. Falissard B (2005) Modèles structuraux (Structural models). In BFalissard (Ed.), Comprendre et utiliser les statistiques dans les sciences de la vie (Understanding and using statistics in life-related sciences) (pp. 203-215). Paris: Masson.
25. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revised. American Psychiatric Association, Washington, DC.
26. Kay SR, Opler LA, Fiszbein A, (1986) Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 149: 439-448.
27. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, et al. (1994) Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 51: 826-836.
28. Tharyan A, Saravanan B, (2000) Insight and psychopathology in schizophrenia. Indian J Psychiatry 42: 421-426.
29. Boyer L, Aghababian V, Richieri R, Loundou A, Padovani R, et al. (2012) Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 36: 271-276.
30. Faget-Agius C, Boyer L, Padovani R, Richieri R, Mundler O, et al. (2012) Schizophrenia with preserved insight is associated with increased perfusion of the precuneus. J Psychiatry Neurosci 37: 110125.
31. Thompson K, Kulkarni J, Sergejew AA, (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42: 241-247.
32. Arduini L, Kalyvoka A, Stratta P, Rinaldi O, Daneluzzo E, et al. (2003) Insight and neuropsychological function in patients with schizophrenia and bipolar disorder with psychotic features. Can J Psychiatry 48: 338-341.
33. Mohamed S, Fleming S, Penn DL, Spaulding W, (1999) Insight in schizophrenia: its relationship to measures of executive functions. J Nerv Ment Dis 187: 525-531.
34. Lysaker PH, Tsai J, Maulucci AM, Stanghellini G, (2008) Narrative accounts of illness in schizophrenia: association of different forms of awareness with neurocognition and social function over time. Conscious Cogn 17: 1143-1151.
35. Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G, (2009) Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother 9: 1035-1043.
36. Davis LW, Eicher AC, Lysaker PH, (2011) Metacognition as a predictor of therapeutic alliance over 26 weeks of psychotherapy in schizophrenia. Schizophr Res 129: 85-90.
37. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC, (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65: 1372-1376.
38. Jaccard J, Wan C (1996) LISREL approaches to interaction effects in multiple regression. Thousand Oaks: Sage Publications.
39. Cohen J (1982) Statistical power analysis for behavioural sciences. Hillsdale, NJ: Lawrence Erlbaum Associates.
40. Aleman A, Agrawal N, Morgan KD, David AS, (2006) Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry 189: 204-212.
41. Langdon R, Ward P, (2009) Taking the perspective of the other contributes to awareness of illness in schizophrenia. Schizophr Bull 35: 1003-1011.
42. Lysaker PH, Dimaggio G, Buck KD, Callaway SS, Salvatore G, et al. (2011) Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiatry 52: 253-260.
43. Alenius M, Hammarlund-Udenaes M, Hartvig P, Lindstrom L, (2010) Knowledge and insight in relation to functional remission in patients with long-term psychotic disorders. Soc Psychiatry Psychiatr Epidemiol 45: 523-529.
44. Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD, (2012) Combined Cognitive Remediation and Functional Skills Training for Schizophrenia: Effects on Cognition, Functional Competence, and Real-World Behavior. Am J Psychiatry.
45. Wolwer W, Frommann N, (2011) Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR). Schizophr Bull 37 Suppl 2: S63-70.
46. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, et al. (2011) Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res 45: 1113-1122.
47. McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, et al. (2012) The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One 7: e36080.
48. Lysaker PH, Buck KD, Carcione A, Procacci M, Salvatore G, et al. (2010) Addressing metacognitive capacity for self reflection in the psychotherapy for schizophrenia: A conceptual model of the key tasks and processes. Psychol Psychother.
49. Salvatore G, Lysaker PH, Gumley A, Popolo R, Mari J, et al. (2012) Out of illness experience: metacognition-oriented therapy for promoting self-awareness in individuals with psychosis. Am J Psychother 66: 85-106.
50. Young DA, Campbell Z, Zakzanis KK, Weinstein E, (2003) A comparison between an interview and a self-report method of insight assessment in chronic schizophrenia. Schizophr Res 63: 103-109.